Gilead is teaming up with Vir on solid tumor cancer drugs in a deal worth up to $1.9 billion

发生了什么

Vir Biotechnology will receive $90 million upfront and could earn up to $1.74 billion in later milestone payments

摘要按规则整理自下方来源原文

来源